



#13  
JL  
2/9/00

BOX PATENT  
Attorney Docket No. AR218-X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gregory S. HAMILTON et al.

Examiner: Celia Chang

Serial No: 09/204,236

Group: 1612

Filed: December 3, 1998

For: **N-LINKED SULFONAMIDES OF HETERO CYCLIC CARBOXYLIC ACIDS OR  
CARBOXYLIC ACID ISOSTERES**

LETTER TO THE EXAMINER  
REGARDING INFORMATION DISCLOSURE STATEMENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants herein provide a brief description of material described in each reference cited in the Information Disclosure Statement, filed July 15, 1999; Supplemental Information Disclosure Statement, filed July 14, 1999; Fourth Supplemental Information Disclosure Statement filed October 8, 1999; and Fifth Supplemental Information Disclosure Statement filed October 21, 1999. A brief description of the material described in each reference cited in the Second Supplemental Information Disclosure Statement, filed October 8, 1999 and the Third Supplemental Information Disclosure Statement, filed October 8, 1999, was provided therewith. This outline is provided for the convenience of the Examiner and to advance the prosecution of the present application before the United States Patent and Trademark Office.

The Examiner's attention is drawn to the following IDS references containing biological information that the Examiner may

find relevant for reviewing the subject matter of the present invention. The identification letters shown below (**AD**, **AE**, etc.) refer to the reference line numbers cited in the respective Information Disclosure Statements.

Nerves- growth of; regeneration; degeneration:

Information Disclosure Statement:

**AA**, **AD**, and **AE**.

First Supplemental Information Disclosure Statement:

**AA**, **AB**, **AE**, **AF**, **AH**, **AO**, **BD**, **BF**, **BG**, **BH**, and **BJ**.

Fourth Supplemental Information Disclosure Statement:

**AA**, **AB**, **AC**, **AD**, **AE**, **AF**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AO**, **AP**,  
**BI**, **CA**, **CB**, **CC**, **CD**, **CE**, **CF**, **CG**, **CH**, **DA**, **DB**, **DC**, **DD**, **DE**,  
**DF**, **DG**, **DH**, **DI**, **DJ**, and **DK**.

Fifth Supplemental Information Disclosure Statement:

**AA**, **AB**, **AC**, **AD**, **AE**, **AF**, **AG**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AT**, and  
**AX**.

Alzheimer's disease:

Information Disclosure Statement:

**AA**, **AC**, **AD**, and **AE**.

First Supplemental Information Disclosure Statement:

**AA**, **AB**, **AE**, **AH**, **AN**, **AO**, **BB**, **BD**, **BF**, **BG**, and **BH**.

Fourth Supplemental Information Disclosure Statement:

**AA**, **AB**, **AD**, **AE**, **AF**, **AH**, **AI**, **AJ**, **AK**, **AL**, **AM**, **AO**, **AP**, **AU**,  
**BI**, **CC**, **CH**, **DA**, and **DJ**.

Fifth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AO, AT,  
AV, and AX.**

Parkinson's disease:

Information Disclosure Statement:

**AA and AD.**

First Supplemental Information Disclosure Statement:

**AA, AB, AE, AH, AO, BD, and BG.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AD, AE, AF, AH, AI, AJ, AK, AL, AM, AO, AP, CH,  
DA, and DI.**

Fifth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AT, and  
AX.**

Amyotrophic lateral sclerosis:

Information Disclosure Statement:

**AA and AD.**

First Supplemental Information Disclosure Statement:

**AA, AB, AE, AG, AH, AM, AN, BE, BG, and BI.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AD, AE, AF, AH, AI, AJ, AK, AL, AM, AP, BE, BF,  
and BG.**

Fifth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AH, AI, AJ, AK, AL, AN, AT, and  
AV.**

Cerebral ischemia:

First Supplemental Information Disclosure Statement:

**AB, AC, BB, and BK.**

Fourth Supplemental Information Disclosure Statement:

**AA, AB, AF, AH, AI, AJ, AL, BC, BI, CA, and DE.**

Fifth Supplemental Information Disclosure Statement:

**AL and AT.**

Degenerative disorders of nervous system; CNS disorders:

Information Disclosure Statement:

**AA and AD.**

First Supplemental Information Disclosure Statement:

**AA, AE, AH, AL, AO, BB, BD, BF, and BH.**

Fourth Supplemental Information Disclosure Statement:

**AD, AE, AF, AK, AM, BI, CD, CH, DF, DI, DJ, and DK.**

Fifth Supplemental Information Disclosure Statement:

**AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AM, and AU.**

Memory or Dementia:

First Supplemental Information Disclosure Statement:

**BB, BC, BF, and BH.**

Fourth Supplemental Information Disclosure Statement:

**AD and AE.**

Fifth Supplemental Information Disclosure Statement:

**AO, AV, and BC.**

Eye or vision, or similar disorders:

Information Disclosure Statement:

**AC** and **AE**.

First Supplemental Information Disclosure Statement:

**AA, AB, AD, AE, AG, AH, AI, AJ, AM, AN, AO, BE, BI, BJ,**  
**and BK.**

Fourth Supplemental Information Disclosure Statement:

**AZ, BC, BE, BF, BG, BQ, BR, and BS.**

Fifth Supplemental Information Disclosure Statement:

**AN, AR, and AS.**

Hair Growth or Alopecia:

Information Disclosure Statement:

**AB, AE, and AF.**

First Supplemental Information Disclosure Statement:

**AC, AD and BA.**

Fourth Supplemental Information Disclosure Statement:

**AC, AF, AG, AQ, AT, AU, AV, AY, BA, BB, BH, BJ, BK, BL,**  
**BM, BN, BO, CJ, CK, and DL.**

The following references disclose chemical structures that the Examiner may find relevant for reviewing the subject matter of the present invention.

Information Disclosure Statement:

**AB, AC, AF, and AG.**

First Supplemental Information Disclosure Statement:

**AA, AB, AK, CA, CB, CC, CD, CE, CF, and DA.**

Fourth Supplemental Information Disclosure Statement:

**AC, AN, AR, AS, AW, AX, AZ, BC, BD, BP, BQ, BT, and CI.**

Fifth Supplemental Information Disclosure Statement:


**AB, AP, AQ, AS, AW, AX, BA, and BB.**

Applicants have taken great care to ensure that the claims of the present invention are patentable over all cited references, but welcome and appreciate the Examiner's consideration of the same.

Please contact the undersigned attorney by telephone should there be any questions or comments.

Respectfully submitted,  
**NATH & ASSOCIATES**

Date: Dec. 30, 1999

  
\_\_\_\_\_  
Gary M. Nath  
Reg. No. 26,965  
Todd L. Juneau  
Reg. No. 40,669

**NATH & ASSOCIATES**

1030 Fifteenth Street, N.W.  
Sixth Floor  
Washington, D.C. 20005  
(202) 775-8383  
GMN:TLJ:JBG:\roadmap



SP/1612

**PATENT BOX**

Attorney Docket No. AR218-X

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Gregory S. HAMILTON et al.

Group Art Unit: 1612

Serial No. 09/204,236

Examiner: Celia Chang

Filed: December 3, 1998

For: **N-LINKED SULFONAMIDES OF HETERO CYCLIC CARBOXYLIC ACIDS OR  
CARBOXYLIC ACID ISOSTERES**

**TRANSMITTAL LETTER**

**RECEIVED**

JAN 03 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

**TECH CENTER 1600/2900**

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal Letter; and
- 2) Letter to the Examiner.

If extensions of time under 37 CFR § 1.136 other than those provided herewith are required to allow consideration of papers accompanying this Petition, then such extensions of time are hereby petitioned. The Commissioner is specifically authorized to charge fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES**

Date: Dec. 30, 1999 By: Todd L. Juneau

Gary M. Nath  
Reg. No. 26,965  
Todd L. Juneau  
Reg. No. 40,669

**NATH & ASSOCIATES**

1030 Fifteenth Street N.W.  
Sixth Floor  
Washington, D.C. 20005-1503  
TEL: (202) 775-8383  
FAX: (202) 775-8396  
GMN:TLJ:JBG:\roadmap.t1